Cytosorbents targets operating cash flow breakeven in 2H 2026 while planning DrugSorb-ATR de novo submission in late 2026/early 2027 (NASDAQ:CTSO)

Cytosorbents (CTSO) Q1 2026 earnings call recap: revenue, margins, cash burn, and FDA DrugSorb-ATR delay plus DOAC upside.

Read on WOBR AI →